Compare IPAR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | BEAM |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | 647 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 1995 | 2019 |
| Metric | IPAR | BEAM |
|---|---|---|
| Price | $92.58 | $27.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 16 |
| Target Price | ★ $125.50 | $49.13 |
| AVG Volume (30 Days) | 225.3K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | 7.79 | ★ 82.31 |
| EPS | ★ 4.36 | N/A |
| Revenue | ★ $1,317,700,000.00 | $24,000.00 |
| Revenue This Year | $4.60 | N/A |
| Revenue Next Year | $9.25 | $35.80 |
| P/E Ratio | $21.95 | ★ N/A |
| Revenue Growth | 21.26 | ★ 33.33 |
| 52 Week Low | $77.21 | $13.53 |
| 52 Week High | $142.50 | $36.44 |
| Indicator | IPAR | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 47.80 |
| Support Level | $92.30 | $25.89 |
| Resistance Level | $101.50 | $29.06 |
| Average True Range (ATR) | 3.46 | 1.91 |
| MACD | -1.34 | 0.00 |
| Stochastic Oscillator | 13.80 | 23.62 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations.. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.